---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-204389"
form_type: "8-K"
ticker: "CRBP"
cik: "0001595097"
company_name: "Corbus Pharmaceuticals Holdings, Inc."
filed_at: "2025-09-16T23:59:59+00:00"
generated_at: "2026-05-17T06:30:00.960263+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# FDA grants Fast Track designation for Corbus' CRB-701 in recurrent/metastatic HNSCC

## Summary
- FDA granted Fast Track for CRB-701 to treat HNSCC after prior platinum and anti-PD(L)-1 therapy.
- Second Fast Track designation for CRB-701; first was for cervical cancer in December 2024.
- Phase 1/2 dose optimization data to be presented at ESMO 2025 on October 19, 2025.
- CRB-701 is a next-generation Nectin-4 targeting ADC with site-specific cleavable linker and MMAE payload (DAR 2).
- Ongoing Phase 1/2 trial evaluating safety, PK, and efficacy in advanced solid tumors with high Nectin-4 expression.

## SEC filing metadata
- accession: 0001193125-25-204389
- form_type: 8-K
- ticker: CRBP
- cik: 0001595097
- company_name: Corbus Pharmaceuticals Holdings, Inc.
- filed_at: 2025-09-16T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595097/000119312525204389/0001193125-25-204389-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595097/000119312525204389/crbp-20250916.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-204389
- JSON: https://secwatch.observer/filing/0001193125-25-204389.json
- Plain text: https://secwatch.observer/filing/0001193125-25-204389.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.